SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Arcolab soars as its arm receives US FDA approval for Zoledronic Acid

06 Mar 2013 Evaluate

Strides Arcolab is currently trading at Rs. 900.30, up by 22.45 points or 2.56% from its previous closing of Rs. 877.85 on the BSE.

The scrip opened at Rs. 884.45 and has touched a high and low of Rs. 905.45 and Rs. 884.45 respectively. So far 119902 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1224.90 on 05-Dec-2012 and a 52 week low of Rs. 542.35 on 06-Mar-2012.

Last one week high and low of the scrip stood at Rs. 1125.00 and Rs. 816.00 respectively. The current market cap of the company is Rs. 5311.74 crore.

The promoters holding in the company stood at 27.51% while Institutions and Non-Institutions held 49.31% and 23.18% respectively.

Agila Specialties, a wholly owned subsidiary of Strides Arcolab has received ANDA approval for Zoledronic Acid Injection 4 mg (base)/ 5ml packaged in Single dose vials. Zoledronic Acid is used to treat high blood calcium levels (hypercalcemia) that may occur with cancer.

According to IMS data, the US market for Zoledronic Acid 5ML is approximately $520 million. The product is expected to be launched shortly.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×